GLP1R and cholangiocarcinoma: In the analyses in which the exclusion criteria related to risk factors of cholangiocarcinoma were not applied, the adjusted HR vs sulfonylureas was 1.15 (95% CI 0.91, 1.45) for DPP4 inhibitors and 1.19 (95% CI 0.85, 1.66) for GLP-1-receptor agonists.